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Aim: To investigate serum levels of ghrelin in pregnant women as a potential early marker for hyperemesis gravidarum (HG).
Materials and methods: A cross-sectional study was carried out at Fatih University Hospital. Included in the study were 35 women
with HG and 31 pregnant women without HG as a control group. The groups were compared in terms of age, gravidity, body mass index
(BMI), and fasting serum thyroid-stimulating hormone (TSH) and ghrelin levels.
Results: Ghrelin levels of the patients with HG were found to be significantly lower than those in the control group (P = 0.03). No
intergroup differences could be found in serum TSH or BMI values .
Conclusion: Ghrelin might serve as a reliable marker in the etiopathogenesis of HG.
Key words: Hyperemesis gravidarum, pregnancy, ghrelin, etiopathogenesis, thyroid-stimulating hormone, body mass index

1. Introduction
Hyperemesis gravidarum (HG), a pregnancy-related
condition marked by extreme nausea and vomiting, occurs
in 0.5%–2% of all pregnancies. This condition usually
begins between the 4th and the 10th weeks of gestation
and disappears spontaneously at the 20th week of gestation
(1). Fluid, electrolyte and acid–base imbalance, nutritional
deficiencies, and weight loss are the expected important
side effects (1). For these reasons, hospitalization and
intravenous hydration therapy or parenteral nutrition
may be necessary. This period may lead to depression
and decrease in the patient’s quality of life. The financial
burden on the health system due to hospitalization and
on the patient due to time lost from work is another
significant problem (2). Furthermore, it is associated with
adverse pregnancy outcomes such as low birth weight and
preterm birth (2).
Although
endocrinological,
psychoneurotic,
environmental, and genetic factors are considered as
potential causes for HG, the extant literature on this
issue does not offer a definitive answer pertaining to the
potential cause (3).
* Correspondence: ikbal_cekmen@yahoo.com
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Ghrelin, a gastric-derived peptide, is known as an
appetite-stimulating hormone (4). It regulates food intake,
energy metabolism, and growth hormone secretion
both by central and peripheral action (5,6). The level of
ghrelin increases before eating and decreases after a meal
(7). Moreover, ghrelin influences sleep; controls gastric
motility, acid secretion, pancreatic secretion, glucose
and lipid metabolism, and cell proliferation; and exerts
cardiovascular and antiinflammatory effects (8,9). It has
recently been reported that ghrelin plays an important
role in reproductive functions, such as the regulation
of gonadal function, gonadotrophin secretion, embryo
development, implantation, and prenatal growth (9–11).
Maternal ghrelin concentration begins to increase in the
first trimester, reaches the highest level at mid-pregnancy,
and reduces to the lowest level in the third trimester (12).
The observed high ghrelin levels in the first trimester of
pregnancy raises the question as to whether this hormone
can serve as a distinctive marker for HG. To answer this
question, we examined the relationship between HG and
ghrelin levels in pregnant women.
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2. Materials and methods
This cross-sectional study was performed at the Medical
School of Fatih University, Ankara, Turkey. Included in the
study were 35 pregnant women with HG and 31 pregnant
women in the first trimester without any symptoms whose
age, prepregnancy weight, and gravidity matched those of
the women in the study group, for a total of 66 cases.
HG was defined as severe nausea and vomiting,
positive ketonuria (++++) in urine samples with no other
detectable causes, and 2 or more hospitalizations during
the present pregnancy because of electrolyte imbalance.
Any patient known to have hepatic and/or renal
dysfunction, gastritis, or thyroid diseases was excluded
from the study.
This study was approved by the Fatih University Ethics
Committee and complied with the Helsinki Declaration,
including current revisions and Good Clinical Practice
guidelines. All the women signed written informed
consent forms before the start of the study.
Both the study and the control groups were examined
with respect to age, parity, and body mass index (BMI). The
gestational age of the pregnancy in weeks was determined
according to the last menstruation date and first trimester
ultrasonographic measurements for both groups. BMI was
calculated as weight in kilograms divided by the square of
height in meters for all subjects.
To determine fasting serum ghrelin and thyroidstimulating hormone (TSH) levels, blood samples were
collected in tubes containing EDTA-Na and aprotinin
between 0830 and 1000 hours, centrifuged immediately at
4 °C, and then frozen at −80 °C for a maximum of 3 months
before processing. Plasma ghrelin levels were determined
using enzyme linked immunosorbent assay (ELISA)
methods (ELISA, Phoenix Pharmaceuticals, Belmont,
CA, USA). TSH was determined by chemiluminometric
assay using an ADVIA Centaur XP immunoassay system
(Siemens Healthcare Diagnostics, Deerfield, IL, USA).

Statistical analyses were performed using SPSS 16.0
for Windows (SPSS Inc., Chicago, IL, USA). Continuous
variables were first inspected for normality of statistical
distribution graphically and by Shapiro–Wilk test. Data
were reported as mean ± standard deviation (SD) or
median with interquartile ranges (IQRs), as appropriate.
The nonparametric Mann–Whitney U test was used
to analyze the significance of the differences between
the control and HG groups. P ≤ 0.05 was used to define
significance in all statistical comparisons.
3. Results
The study included 66 pregnant women between the
6th and 10th gestational weeks. There were 35 pregnant
women diagnosed with HG, who were classified as the
study group, and the remaining 31 women constituted
the control group. Characteristics of the patients are
summarized in the Table. The 2 groups showed similarities
in terms of age, gravidity, preconception body mass index,
and gestational age, as shown in the Table. There were no
differences in TSH levels between the groups. Ghrelin
levels were statistically lower in the HG group (47.0 ± 22.9
ng/mL) than in control subjects (62.4 ± 17.0 ng/mL) (P =
0.026). The Figure shows the ghrelin levels for the groups.
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Figure. Levels of ghrelin between the groups (ng/mL).

Table. Characteristics of patients and levels of ghrelin between the groups.
HG (n = 35)

Control (n = 31)

P-value

Age (years)

29.4 ± 5.6

29.3 ± 4.6

0.87

Gravidity

2.0 (1.0)

2.0 (1.0)

0.77

P-BMI (kg/m2)

23.2 ± 3.2

23.5 ± 4.1

0.86

Gestational age (weeks)

8.2 ± 1.4

8.8 ± 1.5

0.89

47.0 ± 22.9

62.4 ± 17.0

0.03*

1.1 ± 1.4

1.0 ± 0.9

0.45

Ghrelin (ng/mL)
TSH (mIU/L)

Data are mean ± SD or median with IQR. *: Statistically significant.
Abbreviations: HG, hyperemesis gravidarum; P-BMI, preconception body mass index; TSH, thyroid stimulating
hormone.
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4. Discussion
Although some endocrine factors are often cited as
the primary cause for HG, its exact cause still remains
unknown. Several placental products, such as human
chorionic gonadotropin (hCG), estradiol, and thyroid
hormones, are considered to be related to this condition.
HG has a higher incidence when the hCG levels peak,
and in twin and molar pregnancies, which are associated
with elevated hCG levels, HG is more common (13).
Similarly, the symptoms of HG coincide with high
progesterone levels in the first trimester of pregnancy. In
addition, slower intestinal transit and gastric emptying
time, distension of the upper gastrointestinal tract, trace
element and vitamin deficiency, Helicobacter pylori
infection, and environmental and genetic factors are
considered as causes of HG (3). HG has been suggested
to be related to the activity of pyridoxine and Wibowa et
al. found significantly lower concentration levels of total
plasma vitamin B6 in pregnant women with nausea and/or
vomiting. They revealed that vitamin B6 supplementation
significantly affected the clinical symptoms of nausea and
vomiting (14). In a study by Chittumma et al. (15), 650 mg
of ginger or 25 mg of vitamin B6 was given to women with
hyperemesis 3 times per day for 4 days and Rhode’s score
implemented to quantify patients’ nausea. Both ginger
and vitamin B6 were effective for the treatment of nausea
and vomiting in pregnancy. Moreover, ginger was more
effective than vitamin B6.
Because of inconsistent findings, a consensus about
the cause and mechanism of HG has not yet been reached.
Some studies looked over the other peptides that affect
food intake and appetite, such as leptin. They examined the
relationship between the severity of nausea and vomiting
and the alterations in the levels of leptin and found higher
serum leptin levels in pregnant women with HG than in
women without nausea and vomiting (16,17). Although
numerous research studies have been carried out to
elucidate the relationship between maternal serum leptin
levels and HG, this study is, to the best of our knowledge,
the first to investigate the relationship between maternal
serum ghrelin levels and HG. In the present study, maternal
serum ghrelin levels were found to be significantly lower
in the study group than in the control group. Ghrelin is
an orexigenic hormone identified as an endogenous ligand
of the growth hormone secretagogue receptor (ghrelin
receptor) (6). It stimulates food intake (5) and triggers a
positive energy balance through central and peripheral
action (6,7). The level of ghrelin increases before eating
and decreases after a meal (7), which means plasma
ghrelin and oral intake correlate negatively. However, in
the present study, plasma ghrelin levels and reduced oral
intake correlated positively. This suggests that the lower
ghrelin levels are not the result of, but are rather the cause

792

of, reduced oral intake during HG. In the study by Shintani
et al. (6), a single intracerebroventricular injection of
ghrelin caused a significant and dose-related increase
in cumulative food intake in rats. They demonstrated
that ghrelin, a novel orexigenic peptide, activates the
hypothalamic neuropeptide Y/Y1 receptor pathway and
this effect results in antagonizing leptin action in the
body. In another study, Yakabi et al. (18) demonstrated
a significant increase in hypothalamic ghrelin levels in
rats fasted for 24 h and a significant decrease in cisplatintreated rats during the early stage of anorexia, although
their plasma ghrelin levels were comparable. On the other
hand, Hiura et al. (19) found lower plasma ghrelin levels
and feeding activity with cisplatin-based chemotherapy
and reported that the extent of ghrelin reduction correlated
well with adverse events, especially with neutropenia and
anorexia. Furthermore, administration of intravenous
ghrelin improved oral feeding and was effective against
weight loss after total gastrectomy in cancer patients.
Ghrelin is mainly produced in the stomach, but it is
also produced in the central nervous system, kidneys,
heart, parathyroid glands, salivary glands, pituitary, small
intestine, pancreas, hypothalamus, and placenta (20). It
has been reported that both mRNAs for ghrelin and its
functional receptor are present in the human placenta
(primarily in cytotrophoblasts) during normal pregnancy,
and ghrelin levels increase in the first trimester of
pregnancy but not in the third trimester (12). This suggests
a role for this hormone as an autocrine/paracrine factor
for the growth and maintenance of the placenta during
pregnancy.
Ghrelin has an inhibitory effect on human myometrial
contractility in vitro. Low levels of ghrelin in the thirdtrimester myometrium are thought to prepare the
uterus prior to labor (21). However, in term pregnancy,
the placental ghrelin–ghrelin receptor system in the
intrauterine growth restriction of rat models is speculated
to continue to operate for the compensation of fetal
development and fetoplacental circulation (22). It was
proposed that chronic treatment of mothers with ghrelin
during the last stage of pregnancy prompts fetal growth
through stimulation of cell proliferation (23). Moreover, in
small-for-gestational-age neonates, umbilical cord ghrelin
plasma concentrations were higher than in appropriate- and
large-for-gestational-age neonates (24). In another study,
Aydin et al. (25) found higher maternal serum, arterial, and
venous cord blood ghrelin levels in preeclamptic pregnant
women than in healthy controls. They commented on this
increase as a compensatory response to preeclampsia in an
effort to contribute fetal growth, as ghrelin was detected
to be involved in several growth-related processes.
Physiological properties of ghrelin are thought to be a
consequence of its relationship with human placental
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growth hormone, which alters maternal metabolism
during pregnancy by raising maternal insulin resistance, in
order to increase nutrient availability for the fetoplacental
unit (21). Ghrelin induces hyperglycemia and decreases
plasma insulin concentrations, and ghrelin concentrations
decrease with hyperglycemia and hyperinsulinism (25).
Tham et al. (26) found markedly low acylated ghrelin
levels during pregnancy, likely because of a decrease in
the acylation process, and high desacyl ghrelin levels in
gestational diabetes, possibly reflecting resistance to the
inhibitory effect of insulin on ghrelin secretion.
In the present study we found significantly lower
maternal serum ghrelin levels in the HG group than in
the control group. Recent studies have reported a negative
correlation of serum ghrelin levels with food intake in
normal conditions. However, in the present study, plasma
ghrelin levels and reduced oral intake correlated positively.
This suggests that the lower ghrelin levels are not the result
of, but are rather the cause of, reduced oral intake during
HG. However, whether the origin of the ghrelin is placental
or it is secreted from the stomach, hypothalamus, or other
tissues is presently unknown. If we had examined the
source of ghrelin, we could have more easily interpreted
whether the decrease in ghrelin level was due to a decreased
production by the placenta or gastric mucosa, which was
affected by H. pylori infection. Recently a metaanalysis
concluded that circulating ghrelin is significantly lower
in H. pylori-positive subjects (27). Another limitation is
that we did not analyze ghrelin levels in the prepregnancy
period, during the course of pregnancy longitudinally,
after delivery, and in the cord blood. With these analyses,
the effects of ghrelin on the fetus and the ways in which
it affects other pregnancy complications could have

concluded. Another limitation was that we did not analyze
any other etiopathogenic factors that could have affected
ghrelin levels. To have surveyed the level of leptin or to
have determined the presence or absence of H. pylori
infection could have enriched our interpretation. It would
be understandable if there were a balance between leptin
and ghrelin in order to maintain the normal physiology of
pregnancy.
The proposed mechanism for ghrelin to cause HG may
be a fluctuation of circulating ghrelin levels in relation to
meal intake and its effects on appetite, causing nausea and
vomiting to become more severe. Another hypothesis is
that ghrelin may decrease progesterone levels, as suggested
by Rak-Mardyła et al. (28). In the present study, the low
ghrelin levels found for the HG group may be a trigger for
nausea and vomiting, through elevated progesterone levels.
Many pathogenic mechanisms and causes have been
hypothesized and studied to identify the pathogenesis of
HG. However, no consensus on its cause and mechanism
has been reached. Until the etiology and pathogenesis
of HG are known, treatment or patient care will remain
empirical and therefore will be suboptimal. Our study
contributes to this strand of literature by reporting a
significant negative relationship between ghrelin levels
and HG during pregnancy. Prospective studies with a
larger sample size are needed to find out the possible role
of these hormones in the pathogenesis, development, and
management of HG.
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